Burton Lasater Scott
Professor of Neurology
I am a Movement Disorders Neurologist and see patients at the Morreene Rd Clinic and at the Durham VA Medical Center.
Among the types of movement disorders patients that I see in clinic are individuals who have Parkinson's disease, Essential Tremor, tics, chorea, dystonia, Huntington's disease, tardive movement disorders and Wilson's disease. I use botulinum toxin injections to treat selected patients afflicted with dystonia, tremors, and tics. I manage patients who have undergone deep brain stimulation (DBS) for the treatment of Parkinson's disease, Essential Tremor,and dystonia. In addition to managing patients who have movement disorders, I participate in a variety of clinical trials focussed on improving the management and treatment of Parkinson's disease, Huntington's disease, and dystonia.
Key words: movement disorders, Parkinson's disease, tremors, tics, chorea, dystonia, botulinum toxin injections.
Among the types of movement disorders patients that I see in clinic are individuals who have Parkinson's disease, Essential Tremor, tics, chorea, dystonia, Huntington's disease, tardive movement disorders and Wilson's disease. I use botulinum toxin injections to treat selected patients afflicted with dystonia, tremors, and tics. I manage patients who have undergone deep brain stimulation (DBS) for the treatment of Parkinson's disease, Essential Tremor,and dystonia. In addition to managing patients who have movement disorders, I participate in a variety of clinical trials focussed on improving the management and treatment of Parkinson's disease, Huntington's disease, and dystonia.
Key words: movement disorders, Parkinson's disease, tremors, tics, chorea, dystonia, botulinum toxin injections.
Current Appointments & Affiliations
- Professor of Neurology, Neurology, Movement Disorders, Neurology 2021
Contact Information
- 932 Morreene Rd, Durham, NC 27705
- Duke Box 3333, Durham, NC 27710
-
scott007@mc.duke.edu
(919) 668-2493
- Background
-
Education, Training, & Certifications
- Fellow in Neurology, Medicine, Baylor University 1994 - 1995
- Resident in Neurology, Medicine, Duke University 1991 - 1994
- Intern in Medicine, Medicine, Duke University 1990 - 1991
- M.D., University of Miami 1990
- Ph.D., Duke University 1984
-
Previous Appointments & Affiliations
- Professor of Neurology, Neurology, Movement Disorders, Neurology 2013 - 2020
- Associate Professor of Medicine, Neurology, Clinical Science Departments 2006 - 2013
- Associate Clinical Professor of Medicine, Neurology, Clinical Science Departments 2005 - 2006
- Assistant Clinical Professor of Medicine, Neurology, Clinical Science Departments 2001 - 2005
- Associate in the Department of Medicine, Neurology, Clinical Science Departments 1995 - 2001
- Research
-
Selected Grants
- PRidopidine Outcome On Function in Huntington Disease (PROOF-HD) awarded by Prilenia Therapeutics 2020 - 2025
- A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington¿s Disease awarded by Sage Therapeutics 2022 - 2024
- Open Label Rollover Study of Valbenazine for the treatment of HD awarded by Neurocrine Biosciences, Inc. 2020 - 2024
- Phase 2b, 12 Week, Double-blind, Placebo-Controlled, Randomized, Parallel-group, MultiCenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults with Moderate to Severe Essential Tremor awarded by Cavion, Inc 2022 - 2024
- Huntington's Disease Society of America- Center of Excellence (Level 2) awarded by Huntington's Disease Society of America 2023
- A Phase 3, Long-Term, Randomized, Double-Blind, Placebo-Controlled trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia awarded by Biohaven Pharmaceuticals 2019 - 2023
- Enabling Efficient, Fast, Biocompatible Exosome Separation via Acoustofluidics awarded by National Institutes of Health 2019 - 2023
- Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort (A CHDI Foundation Project) awarded by CHDI Foundation 2012 - 2023
- wAID-P Study awarded by University of Florida 2021 - 2023
- A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects with, or at Risk for, Manifest Huntington's Disease awarded by Annexon Biosciences 2020 - 2022
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease awarded by Neurocrine Biosciences, Inc. 2019 - 2022
- Huntington's Disease Society of America- Center of Excellence (Level 2) awarded by Huntington's Disease Society of America 2015 - 2022
- A Phase 2, multi-center, randomized, double blind, placebo controlled study in subjects with late prodromal and early manifest Huntington Disease )HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 awarded by Vaccinex, Inc. 2015 - 2021
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease. (SPARK) awarded by Biogen, Inc. 2018 - 2021
- ROPAD (Rostock International Parkinson's Disease Study): An International, MultiCenter, Epidemiological Observational Study awarded by Centogene AG 2019 - 2021
- Novel Combinatorial Screening for NTFs, NPCs, MMPs, and CCs in relevance to Autoantibodies in the Serum and CSF of Veterans with GWI awarded by Department of Defense 2018 - 2021
- A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients with Parkinson's Disease awarded by AbbVie Inc. 2019 - 2020
- A Randomized, double-blind, placebo-controlled trial of urate elevating inosine treatment to show clinical decline in early Parkinson Disease awarded by Massachusetts General Hospital 2015 - 2020
- A Randomized,Double-Blind,Placebo-Controlled,Phase IIa,Parallel Group, Two-Cohort Study to Define the Safety, Tolerability,Clinical and Exploratory Biological Activity of the ChronicAdministration of Nilotinib in Participants with Parkinson's Disease awarded by Michael J. Fox Foundation for Parkinson's Research 2017 - 2020
- Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD) awarded by Eli Lilly and Company 2018 - 2019
- A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in Subjects with Parkinson's Disease and Excessive Sleep awarded by Jazz Pharmaceuticals 2017 - 2019
- Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects with Parkinson's Disease Psychosis awarded by Sunovion Pharmaceuticals, Inc 2017 - 2019
- An Open label, Long Term Safety Study of SD-809 Er in Subjects wtih Chorea associated with Huntington's Disease. awarded by Auspex Pharmaceuticals, Inc. 2013 - 2019
- A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects with Early Parkinson's Disease awarded by Biogen Idec Inc. 2017 - 2019
- A 15 Week, Phase 2, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Efficacy, Safety and Tolerability of PF 06649751 in Subjects with Motor Fluctuations due to PD awarded by Pfizer, Inc. 2016 - 2018
- A Phase 3, Long-term, Open-label Study of Istradefylline in subjects with moderate to Severe Parkinson's Disease awarded by Kyowa Hakko Kirin Pharma Co, Ltd. 2016 - 2018
- A Ph.3,Multicenter,Randomized,Doubleblind,Placebo-controlledStudy with anOpenlabelPhase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in LevodopaTreated patients with Parkinson's disease ExperiencingEndofdose "Wearing Off" awarded by Biotie Therapies Corp. 2015 - 2018
- A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off" awarded by Biotie Therapies Corp. 2017 - 2018
- National Parkinson Foundation Center of Excellence Grant awarded by National Parkinson Foundation 2017 - 2018
- OL Phase 3 Study Long-Term Safety of APL-130277 in Levodopa responsive patients with Parkinson's Disease Complicated by Motor Fluctuations- (OFF episodes) awarded by Cynapsus Therapeutics Inc. 2015 - 2018
- SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) awarded by Biotie Therapies Corp. 2016 - 2018
- A Randomized, Double-Blind, Placebo-controlled Study of SD-809 (Dutetrabenazine) for the Treatement of Moderate to Severe Tardive Dyskinesia awarded by Auspex Pharmaceuticals, Inc. 2014 - 2016
- A Phase 3, Randomized, Double-blind, Placebo controlled, Parrallel, Fixed Dose Study to Assess the Efficacy, Safety and Tolerability of NBI 98854 for the treatment of Tardive Dyskinesia awarded by Neurocrine Biosciences, Inc. 2014 - 2015
- An Open-Label, Long-Term Safety Study of SD-809 (Dutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia awarded by Auspex Pharmaceuticals, Inc. 2014 - 2015
- A Clinical Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension to assess sustained effects of droxidopa therapy awarded by Chelsea Therapeutics 2014 - 2015
- Creatine Safety, Tolerability and Efficacy in Huntington's Disease: CREST-E awarded by Massachusetts General Hospital 2014 - 2015
- A Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease awarded by Scion NeuroStim LLC 2014 - 2015
- Parkinson's Disease Neuroprotection Clinical Trial (Closeout Activities Budget) awarded by National Institutes of Health 2002 - 2014
- Genetics and epidemiology of essential tremor awarded by National Institutes of Health 2002 - 2007
-
External Relationships
- Deep Brain Innovations
- HD Reach. Started on Board of Director in January 2020.
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Bukhari-Parlakturk, Noreen, Michael W. Lutz, Hussein R. Al-Khalidi, Shakthi Unnithan, Joyce En-Hua Wang, Burton Scott, Pichet Termsarasab, Lawrence G. Appelbaum, and Nicole Calakos. “Suitability of Automated Writing Measures for Clinical Trial Outcome in Writer's Cramp.” Mov Disord 38, no. 1 (January 2023): 123–32. https://doi.org/10.1002/mds.29237.Full Text Link to Item
-
Feigin, Andrew, Elizabeth E. Evans, Terrence L. Fisher, John E. Leonard, Ernest S. Smith, Alisha Reader, Vikas Mishra, et al. “Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.” Nat Med 28, no. 10 (October 2022): 2183–93. https://doi.org/10.1038/s41591-022-01919-8.Full Text Link to Item
-
Mitchell, Kyle T., Stephen L. Schmidt, Jeffrey W. Cooney, Warren M. Grill, Jennifer Peters, Shervin Rahimpour, Hui-Jie Lee, et al. “Initial Clinical Outcome With Bilateral, Dual-Target Deep Brain Stimulation Trial in Parkinson Disease Using Summit RC + S.” Neurosurgery 91, no. 1 (July 1, 2022): 132–38. https://doi.org/10.1227/neu.0000000000001957.Full Text Open Access Copy Link to Item
-
Feigin, A., E. E. Evans, T. L. Fisher, J. E. Leonard, E. S. Smith, A. Reader, V. Mishra, et al. “Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8).” Nature Medicine, January 1, 2022. https://doi.org/10.1038/s41591-022-02070-0.Full Text
-
Robbins, Cason B., Dilraj S. Grewal, Atalie C. Thompson, Srinath Soundararajan, Stephen P. Yoon, Bryce W. Polascik, Burton L. Scott, and Sharon Fekrat. “Identifying Peripapillary Radial Capillary Plexus Alterations in Parkinson's Disease Using OCT Angiography.” Ophthalmol Retina 6, no. 1 (January 2022): 29–36. https://doi.org/10.1016/j.oret.2021.03.006.Full Text Link to Item
-
McIntosh, Paul, and Burton Scott. “Clinical Reasoning: A 55-Year-Old Man With Odd Behavior and Abnormal Movements.” Neurology 97, no. 23 (December 7, 2021): 1090–93. https://doi.org/10.1212/WNL.0000000000012663.Full Text Link to Item
-
Ma, Justin P., Cason B. Robbins, Sandra S. Stinnett, Kim G. Johnson, Burton L. Scott, Dilraj S. Grewal, and Sharon Fekrat. “Repeatability of Peripapillary OCT Angiography in Neurodegenerative Disease.” Ophthalmol Sci 1, no. 4 (December 2021): 100075. https://doi.org/10.1016/j.xops.2021.100075.Full Text Open Access Copy Link to Item
-
Parkinson Study Group SURE-PD3 Investigators, Tiago, Michael A. Schwarzschild, Alberto Ascherio, Cindy Casaceli, Gary C. Curhan, Rebecca Fitzgerald, Cornelia Kamp, et al. “Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.” Jama 326, no. 10 (September 14, 2021): 926–39. https://doi.org/10.1001/jama.2021.10207.Full Text Link to Item
-
Shah-Zamora, Deepal, Allison M. Allen, Lacy Rardin, Margaret Ivancic, Katie Durham, Patrick Hickey, Jeffrey W. Cooney, Burton L. Scott, and Sneha Mantri. “Mindfulness based stress reduction in people with Parkinson's disease and their care partners.” Complement Ther Clin Pract 43 (May 2021): 101377. https://doi.org/10.1016/j.ctcp.2021.101377.Full Text Open Access Copy Link to Item
-
Robbins, Cason B., Atalie C. Thompson, Paramjit K. Bhullar, Hui Yan Koo, Rupesh Agrawal, Srinath Soundararajan, Stephen P. Yoon, et al. “Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease.” Jama Ophthalmol 139, no. 2 (February 1, 2021): 182–88. https://doi.org/10.1001/jamaophthalmol.2020.5730.Full Text Link to Item
-
Frank, Samuel, David Stamler, Elise Kayson, Daniel O. Claassen, Amy Colcher, Charles Davis, Andrew Duker, et al. “Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.” Jama Neurol 74, no. 8 (August 1, 2017): 977–82. https://doi.org/10.1001/jamaneurol.2017.1352.Full Text Link to Item
-
McGarry, Andrew, Michael McDermott, Karl Kieburtz, Elisabeth A. de Blieck, Flint Beal, Karen Marder, Christopher Ross, et al. “A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.” Neurology 88, no. 2 (January 10, 2017): 152–59. https://doi.org/10.1212/WNL.0000000000003478.Full Text Link to Item
-
Hickey, Patrick T., Maragatha Kuchibhatla, Burton Scott, Lisa Gauger, and Mark A. Stacy. “Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinson's Disease.” J Parkinsons Dis 7, no. 2 (2017): 279–87. https://doi.org/10.3233/JPD-160937.Full Text Link to Item
-
Rittiner, Joseph E., Zachary F. Caffall, Ricardo Hernández-Martinez, Sydney M. Sanderson, James L. Pearson, Kaylin K. Tsukayama, Anna Y. Liu, et al. “Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2α Signaling as a Generalizable Mechanism for Dystonia.” Neuron 92, no. 6 (December 21, 2016): 1238–51. https://doi.org/10.1016/j.neuron.2016.11.012.Full Text Link to Item
-
Huntington Study Group, Emily, Samuel Frank, Claudia M. Testa, David Stamler, Elise Kayson, Charles Davis, Mary C. Edmondson, et al. “Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.” Jama 316, no. 1 (July 5, 2016): 40–50. https://doi.org/10.1001/jama.2016.8655.Full Text Link to Item
-
Hicks, James E., Ioanna Konidari, Burton L. Scott, Jeffrey M. Stajich, Allison E. Ashley-Koch, John R. Gilbert, and William K. Scott. “Linkage of familial essential tremor to chromosome 5q35.” Mov Disord 31, no. 7 (July 2016): 1059–62. https://doi.org/10.1002/mds.26582.Full Text Link to Item
-
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators, N. I. N. D. S. N. E. T. -. P. D. F. S. -. Z. O. N. E. “Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.” Lancet Neurol 14, no. 8 (August 2015): 795–803. https://doi.org/10.1016/S1474-4422(15)00144-1.Full Text Open Access Copy Link to Item
-
Marck, Marjolein A. van der, Margit Ph C. Klok, Michael S. Okun, Nir Giladi, Marten Munneke, Bastiaan R. Bloem, and Bastiaan R. NPF Falls Task Force. “Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease.” Parkinsonism Relat Disord 20, no. 4 (April 2014): 360–69. https://doi.org/10.1016/j.parkreldis.2013.10.030.Full Text Link to Item
-
HORIZON Investigators of the Huntington Study Group and European Huntington’s Disease Network, Z. “A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.” Jama Neurol 70, no. 1 (January 2013): 25–33. https://doi.org/10.1001/2013.jamaneurol.382.Full Text Link to Item
-
Jacks, A., K. L. Haley, B. L. Scott, and H. Jones. “Auditory-perceptual analysis of dysarthria in bilateral striatopallidodentate calcinosis (fahr's disease).” Journal of Medical Speech Language Pathology 20, no. 1 (March 1, 2012): 29–34.Open Access Copy
-
Parkinson Study Group POETRY Investigators, Lisa Helene. “A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease.” Parkinsonism Relat Disord 17, no. 10 (December 2011): 757–60. https://doi.org/10.1016/j.parkreldis.2011.07.007.Full Text Link to Item
-
Bryson, W. J., C. L. Edwards, D. B. Sommer, and B. L. Scott. “Integrated behavior therapy in the treatment of complicated Tourette's disorder and Its comorbidities.” Clinical Case Studies 9, no. 3 (June 1, 2010): 181–90. https://doi.org/10.1177/1534650110368261.Full Text
-
Bryson, W. J., C. L. Edwards, D. B. Sommer, and B. L. Scott. “Integrated behavior therapy in the treatment of complicated tourette's disorder and its comorbidities.” Clinical Case Studies 9, no. 2 (April 1, 2010): 154–63. https://doi.org/10.1177/1534650109357929.Full Text
-
Edwards, Todd L., William K. Scott, Cherylyn Almonte, Amber Burt, Eric H. Powell, Gary W. Beecham, Liyong Wang, et al. “Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.” Ann Hum Genet 74, no. 2 (March 2010): 97–109. https://doi.org/10.1111/j.1469-1809.2009.00560.x.Full Text Link to Item
-
Wingo, Thomas S., Marian Evatt, Burton Scott, Alan Freeman, and Mark Stacy. “Impulse control disorders arising in 3 patients treated with rotigotine.” Clin Neuropharmacol 32, no. 2 (2009): 59–62. https://doi.org/10.1097/WNF.0B013E3181684542.Full Text Link to Item
-
Stocchi, Fabrizio, Bonnie P. Hersh, Burton L. Scott, Paul A. Nausieda, Luigi Giorgi, and Luigi Ease-PD Monotherapy Study Investigators. “Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study.” Curr Med Res Opin 24, no. 10 (October 2008): 2883–95. https://doi.org/10.1185/03007990802387130.Full Text Link to Item
-
Hancock, Dana B., Eden R. Martin, Gregory M. Mayhew, Jeffrey M. Stajich, Rita Jewett, Mark A. Stacy, Burton L. Scott, Jeffery M. Vance, and William K. Scott. “Pesticide exposure and risk of Parkinson's disease: a family-based case-control study.” Bmc Neurol 8 (March 28, 2008): 6. https://doi.org/10.1186/1471-2377-8-6.Full Text Link to Item
-
Kieburtz, K., B. Tilley, B. Ravina, W. R. Galpern, K. Shannon, C. Tanner, G. F. Wooten, et al. “A pilot clinical trial of creatine and minocycline in early parkinson disease: 18-month results.” Clinical Neuropharmacology 31, no. 3 (January 1, 2008): 141–50. https://doi.org/10.1097/WNF.0b013e3181342f32.Full Text
-
Hancock, Dana B., Eden R. Martin, Jeffrey M. Stajich, Rita Jewett, Mark A. Stacy, Burton L. Scott, Jeffery M. Vance, and William K. Scott. “Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease.” Arch Neurol 64, no. 4 (April 2007): 576–80. https://doi.org/10.1001/archneur.64.4.576.Full Text Link to Item
-
NINDS NET-PD Investigators, E. J. “A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.” Neurology 68, no. 1 (January 2, 2007): 20–28. https://doi.org/10.1212/01.wnl.0000250355.28474.8e.Full Text Link to Item
-
Lang, A. E., S. Gill, N. K. Patel, A. Lozano, J. G. Nutt, R. Penn, D. J. Brooks, et al. “Erratum: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease (Annals of Neurology (2006) 59 (459-466)).” Annals of Neurology 60, no. 6 (December 1, 2006): 747. https://doi.org/10.1002/ana.21061.Full Text
-
Hancock, Dana B., Eden R. Martin, Kenichiro Fujiwara, Mark A. Stacy, Burton L. Scott, Jeffrey M. Stajich, Rita Jewett, et al. “NOS2A and the modulating effect of cigarette smoking in Parkinson's disease.” Ann Neurol 60, no. 3 (September 2006): 366–73. https://doi.org/10.1002/ana.20915.Full Text Link to Item
-
NINDS NET-PD Investigators, Diana J. “A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.” Neurology 66, no. 5 (March 14, 2006): 664–71. https://doi.org/10.1212/01.wnl.0000201252.57661.e1.Full Text Link to Item
-
Lang, Anthony E., Steven Gill, Nik K. Patel, Andres Lozano, John G. Nutt, Richard Penn, David J. Brooks, et al. “Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.” Ann Neurol 59, no. 3 (March 2006): 459–66. https://doi.org/10.1002/ana.20737.Full Text Link to Item
-
Noureddine, Maher A., Yi-Ju Li, Joelle M. van der Walt, Robert Walters, Rita M. Jewett, Hong Xu, Tianyuan Wang, et al. “Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra.” Mov Disord 20, no. 10 (October 2005): 1299–1309. https://doi.org/10.1002/mds.20573.Full Text Link to Item
-
Hauser, Michael A., Yi-Ju Li, Hong Xu, Maher A. Noureddine, Yujun S. Shao, Steven R. Gullans, Clemens R. Scherzer, et al. “Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.” Arch Neurol 62, no. 6 (June 2005): 917–21. https://doi.org/10.1001/archneur.62.6.917.Full Text Link to Item
-
Scott, W. K., F. Zhang, J. M. Stajich, B. L. Scott, M. A. Stacy, and J. M. Vance. “Family-based case-control study of cigarette smoking and Parkinson disease.” Neurology 64, no. 3 (February 8, 2005): 442–47. https://doi.org/10.1212/01.WNL.0000150905.93241.B2.Full Text Link to Item
-
Parkinson Study Group, Penny. “A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.” Arch Neurol 62, no. 2 (February 2005): 241–48. https://doi.org/10.1001/archneur.62.2.241.Full Text Link to Item
-
Oliveira, Sofia A., William K. Scott, Fengyu Zhang, Jeffrey M. Stajich, Kenichiro Fujiwara, Michael Hauser, Burton L. Scott, Margaret A. Pericak-Vance, Jeffery M. Vance, and Eden R. Martin. “Linkage disequilibrium and haplotype tagging polymorphisms in the Tau H1 haplotype.” Neurogenetics 5, no. 3 (September 2004): 147–55. https://doi.org/10.1007/s10048-004-0180-5.Full Text Link to Item
-
Walt, Joelle M. van der, Maher A. Noureddine, Raja Kittappa, Michael A. Hauser, William K. Scott, Ron McKay, Fengyu Zhang, et al. “Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease.” Am J Hum Genet 74, no. 6 (June 2004): 1121–27. https://doi.org/10.1086/421052.Full Text Link to Item
-
Myers, Bennett H., and Burton L. Scott. “A case of combined orthostatic tremor and primary gait ignition failure.” Clin Neurol Neurosurg 105, no. 4 (September 2003): 277–80. https://doi.org/10.1016/s0303-8467(03)00032-5.Full Text Link to Item
-
Oliveira, Sofia A., William K. Scott, Martha A. Nance, Ray L. Watts, Jean P. Hubble, William C. Koller, Kelly E. Lyons, et al. “Association study of Parkin gene polymorphisms with idiopathic Parkinson disease.” Arch Neurol 60, no. 7 (July 2003): 975–80. https://doi.org/10.1001/archneur.60.7.975.Full Text Link to Item
-
Oliveira, Sofia A., William K. Scott, Eden R. Martin, Martha A. Nance, Ray L. Watts, Jean P. Hubble, William C. Koller, et al. “Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.” Ann Neurol 53, no. 5 (May 2003): 624–29. https://doi.org/10.1002/ana.10524.Full Text Link to Item
-
Walt, J. M. van der, E. R. Martin, W. K. Scott, F. Zhang, M. A. Nance, R. L. Watts, J. P. Hubble, et al. “Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease.” Neurology 60, no. 7 (April 8, 2003): 1189–91. https://doi.org/10.1212/01.wnl.0000055929.84668.9a.Full Text Link to Item
-
Walt, Joelle M. van der, Kristin K. Nicodemus, Eden R. Martin, William K. Scott, Martha A. Nance, Ray L. Watts, Jean P. Hubble, et al. “Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease.” Am J Hum Genet 72, no. 4 (April 2003): 804–11. https://doi.org/10.1086/373937.Full Text Link to Item
-
Li, Y. J., W. K. Scott, D. K. Hedges, F. Y. Zhang, P. C. Gaskell, J. M. Stajich, A. M. Saunders, et al. “Location of common age-at onset genes in Alzheimer and Parkinson diseases.” Neurobiology of Aging 23, no. 1 (July 1, 2002): S317–S317.Link to Item
-
Li, Yi-Ju, William K. Scott, Dale J. Hedges, Fengyu Zhang, P Craig Gaskell, Martha A. Nance, Ray L. Watts, et al. “Age at onset in two common neurodegenerative diseases is genetically controlled.” Am J Hum Genet 70, no. 4 (April 2002): 985–93. https://doi.org/10.1086/339815.Full Text Link to Item
-
Schenkman, M., T. M. Cutson, M. Kuchibhatla, B. L. Scott, and E. M. Cress. “Application of the continuous scale physical functional performance test to people with parkinson disease.” Neurology Report 26, no. 3 (January 1, 2002): 130–38. https://doi.org/10.1097/01253086-200226030-00004.Full Text
-
Martin, E. R., W. K. Scott, M. A. Nance, R. L. Watts, J. P. Hubble, W. C. Koller, K. Lyons, et al. “Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease.” Jama 286, no. 18 (November 14, 2001): 2245–50. https://doi.org/10.1001/jama.286.18.2245.Full Text Link to Item
-
Scott, W. K., M. A. Nance, R. L. Watts, J. P. Hubble, W. C. Koller, K. Lyons, R. Pahwa, et al. “Complete genomic screen in Parkinson disease: evidence for multiple genes.” Jama 286, no. 18 (November 14, 2001): 2239–44. https://doi.org/10.1001/jama.286.18.2239.Full Text Link to Item
-
Oliveira, S. A., E. R. Martin, W. K. Scott, M. A. Nance, R. L. Watts, J. P. Hubble, W. C. Koller, et al. “Association of tau with late-onset Parkinson disease.” American Journal of Human Genetics 69, no. 4 (October 1, 2001): 511–511.Link to Item
-
Scott, W. K., J. M. Stajich, B. L. Scott, M. A. Nance, R. L. Watts, J. P. Hubble, J. L. Haines, et al. “Complete genomic screen in idiopathic Parkinson disease.” American Journal of Human Genetics 69, no. 4 (October 1, 2001): 513–513.Link to Item
-
Scott, W. K., A. R. Rogala, E. Rampersaud, J. M. Stajich, M. A. Nance, R. L. Watts, J. P. Hubble, et al. “Parkin mutations and idiopathic Parkinson disease (PD).” American Journal of Human Genetics 67, no. 4 (October 1, 2000): 19–19.Link to Item
-
Scott, B. L. “Evaluation and treatment of dystonia.” South Med J 93, no. 8 (August 2000): 746–51.Link to Item
-
Scott, B. L. “Evaluation and treatment of dystonia.” Southern Medical Journal 93, no. 8 (August 1, 2000): 745–51.Link to Item
-
Palmer, C. S., J. K. Schmier, E. Snyder, and B. Scott. “Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease.” Qual Life Res 9, no. 7 (2000): 819–27. https://doi.org/10.1023/a:1008903126315.Full Text Link to Item
-
Scott, W. K., L. H. Yamaoka, J. M. Stajich, B. L. Scott, J. M. Vance, A. D. Roses, M. A. Pericak-Vance, et al. “The alpha-synuclein gene is not a major risk factor in familial Parkinson disease.” Neurogenetics 2, no. 3 (September 1999): 191–92. https://doi.org/10.1007/s100480050083.Full Text Link to Item
-
Matthew, W. D., J. R. Guyton, B. L. Scott, and W. J. Strittmatter. “Apolipoprotein E and neural survival.” Experimental Neurology 151, no. 1 (May 1, 1998): 151–52.Link to Item
-
Scott, B. L., K. Welch, V. deSerrano, N. C. Moss, A. D. Roses, and W. J. Strittmatter. “Human apolipoprotein E accelerates microtubule polymerization in vitro.” Neurosci Lett 245, no. 2 (April 3, 1998): 105–8. https://doi.org/10.1016/s0304-3940(98)00180-3.Full Text Link to Item
-
Jankovic, J., B. L. Scott, and R. W. Evans. “Treatment of palatal myoclonus with sumatriptan.” Mov Disord 12, no. 5 (September 1997): 818. https://doi.org/10.1002/mds.870120537.Full Text Link to Item
-
Scott, B. L., R. W. Evans, and J. Jankovic. “Treatment of palatal myoclonus with sumatriptan.” Mov Disord 11, no. 6 (November 1996): 748–51. https://doi.org/10.1002/mds.870110628.Full Text Link to Item
-
Scott, B. L., J. Jankovic, and D. T. Donovan. “Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome.” Mov Disord 11, no. 4 (July 1996): 431–33. https://doi.org/10.1002/mds.870110413.Full Text Link to Item
-
Scott, B. L., and J. Jankovic. “Reply from the Authors: Delayed-onset dyskinesias.” Neurology 47, no. 5 (January 1, 1996): 1359. https://doi.org/10.1212/WNL.47.5.1359.Full Text
-
Scott, B. L., and J. Jankovic. “Delayed-onset progressive movement disorders after static brain lesions.” Neurology 46, no. 1 (January 1996): 68–74. https://doi.org/10.1212/wnl.46.1.68.Full Text Link to Item
-
Strittmatter, W. J., J. R. Burke, V. S. DeSerrano, D. Y. Huang, W. Matthew, A. M. Saunders, B. L. Scott, J. M. Vance, K. H. Weisgraber, and A. D. Roses. “Protein: protein interactions in Alzheimer's disease and the CAG triplet repeat diseases.” Cold Spring Harb Symp Quant Biol 61 (1996): 597–605.Link to Item
-
Turner, D. A., B. L. Scott, P. B. Johnson, and J. Gorecki. “Resurgence of stereotaxic procedures for relief of parkinsonism. Role of image-directed targeting and current status.” N C Med J 57, no. 5 (1996): 320–24.Link to Item
-
SCOTT, B. L., K. A. TAYLOR, and J. M. CORLESS. “A 3-DIMENSIONAL RECONSTRUCTION OF CRYSTALLINE RHODOPSIN MEMBRANES.” Biophysical Journal 45, no. 2 (January 1, 1984): A339–A339.Link to Item
-
SCOTT, B. L., and J. M. CORLESS. “RHODOPSIN, NOT PORPHYROPSIN, IS PRESENT IN VISUAL PIGMENT CRYSTAL PREPARATIONS.” Anatomical Record 208, no. 3 (January 1, 1984): A160–A160.Link to Item
-
Scott, Burton L., Kenneth A. Taylor, and Joseph M. Corless. “A 3-dimensional study of membrane crystals of rhodopsin.” Vision Research 24, no. 11 (January 1984): 1694–1694. https://doi.org/10.1016/0042-6989(84)90336-5.Full Text
-
Corless, J. M., D. R. McCaslin, and B. L. Scott. “Two-dimensional rhodopsin crystals from disk membranes of frog retinal rod outer segments.” Proc Natl Acad Sci U S A 79, no. 4 (February 1982): 1116–20. https://doi.org/10.1073/pnas.79.4.1116.Full Text Link to Item
-
SCOTT, B. L. “CRYSTALLINE MITOCHONDRIAL INCLUSIONS IN THE FROG ROD INNER SEGMENT.” Biophysical Journal 37, no. 2 (January 1, 1982): A87–A87.Link to Item
-
SCOTT, B. L., D. R. MCCASLIN, and J. M. CORLESS. “TWO-DIMENSIONAL CRYSTALS IN DETERGENT-EXTRACTED DISK MEMBRANES FROM FROG ROD OUTER SEGMENTS (ROS).” Biophysical Journal 33, no. 2 (January 1, 1981): A293–A293.Link to Item
-
-
Conference Papers
-
Ma, Justin P., Cason Robbins, Emma Pead, Sarah McGrory, Charlene Hamid, Dilraj Singh Grewal, Burton L. Scott, Emanuele Trucco, Thomas MacGillivray, and Sharon Fekrat. “Retinal vascular changes in Parkinson's disease on ultra-widefield retinal imaging.” In Investigative Ophthalmology & Visual Science, Vol. 62, 2021.Link to Item
-
Hickey, P. T., M. Kuchibhatla, B. L. Scott, L. Gauger, and M. A. Stacy. “Assessment of outcomes in Parkinson's disease subjects randomized to SPECT imaging of the dopamine transporter.” In Movement Disorders, 30:S381–82. WILEY-BLACKWELL, 2015.Link to Item
-
Edmondson, M., D. Lo, S. Dawson, F. Walker, B. Scott, D. Keelean-Fuller, J. Canning, L. W. Bolton, and Lauren Holder. “HD Reach: A Collaborative Model of Healthcare Delivery for Huntington's Disease Patients and Families.” In Neurotherapeutics, 11:225–225. SPRINGER, 2014.Link to Item
-
Wingo, T. S., M. Evatt, B. Scott, A. Freeman, and M. Stacy. “Impulse control disorders arising in three patients treated with rotigotine.” In Movement Disorders, 23:1351–1351. WILEY-LISS, 2008.Link to Item
-
Hauser, M. A., M. Noureddine, J. W. Walter, R. W. Walters, C. M. Hulette, D. E. Schmechel, M. L. Bembe, et al. “Genomic convergence: Identification of candidate genes for Parkinson Disease (PD) using genetic linkage and gene expression in the substantia nigra.” In American Journal of Human Genetics, 73:507–507. UNIV CHICAGO PRESS, 2003.Link to Item
-
Oliveira, S. A., E. R. Martin, W. K. Scott, F. Zhang, J. M. Stajich, L. T. Middleton, A. D. Roses, et al. “Defining the linkage disequilibrium region containing the Tau gene and identifying haplotype tagging polymorphisms.” In American Journal of Human Genetics, 73:532–532. UNIV CHICAGO PRESS, 2003.Link to Item
-
Oliveira, S. A., F. Y. Zhang, W. K. Scott, M. A. Nance, R. L. Watts, J. P. Hubble, W. C. Koller, et al. “Characterization of Tau association with Parkinson disease.” In Annals of Neurology, 54:S50–S50. WILEY-LISS, 2003.Link to Item
-
Hauser, M. A., J. W. Walter, R. W. Walters, M. Maready, S. Takeuchi, W. P. Segars, C. M. Hulette, et al. “Identification of candidate genes for Parkinson disease (PD)by the convergence of genetic linkage and association data with gene expression in the substantia nigra.” In American Journal of Human Genetics, 71:467–467. UNIV CHICAGO PRESS, 2002.Link to Item
-
Schenkman, M., T. M. Cutson, M. Kuchibhatia, B. L. Scott, and M. E. Cress. “Validity of the CS-PFP as a measure of physical functional capacity of those in early/mid-stage Parkinson's disease.” In Gerontologist, 41:282–282. GERONTOLOGICAL SOCIETY AMER, 2001.Link to Item
-
Hubble, J. P., C. C. Weeks, M. Nance, R. L. Watts, W. C. Koller, M. B. Stern, A. Colcher, et al. “Parkinson's disease: Clinical features in sibships.” In Neurology, 52:A13–A13. LIPPINCOTT WILLIAMS & WILKINS, 1999.Link to Item
-
SCOTT, B., and J. JANKOVIC. “DELAYED-ONSET PROGRESSIVE MOVEMENT-DISORDERS AFTER STATIC BRAIN-LESIONS.” In Neurology, 45:A186–A186. LITTLE BROWN CO, 1995.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.